Stryker’s recent FDA clearance of Sonopet 3 and the $400M robotics acquisition reinforce its high‑margin growth trajectory, while Q2 earnings beat expectations. Technical indicators show a sustained uptrend with 50‑day MA above 200‑day MA, supporting a bullish outlook.

Investor enthusiasm for Stryker’s expanding surgical platform is reflected in rising volume and positive analyst upgrades. The broader medical device market remains resilient, keeping Stryker’s sentiment bullish.

While the robotics deal adds leverage risk, the company’s diversified portfolio and strong cash flow mitigate long‑term downside, making the long‑term outlook bullish.

RSI is at 58, below overbought, and the 20‑day EMA is converging upward, indicating a bullish momentum; volume spikes confirm the trend.